PRELIMINARY-RESULTS OF PHASE-1 AND PHASE-2 CLINICAL-TRIALS OF RFCNU, A NEW NITROSOUREA SUGAR DERIVATIVE, IN DIGESTIVE-TRACT TUMORS

  • 1 January 1977
    • journal article
    • research article
    • Vol. 27  (8) , 294-297
Abstract
RFCNU [(chloro-2-ethyl)-1-(ribofuranosyl-isopropylidene-2'', 3'' paranitrobenzoate-5'')-3 nitrosourea], a new synthetic nitrosourea derivative, which had, among all nitrosourea derivatives tested in mice, the longest maximally efficient dose interval (MEDI) and which is not immunosuppressive at the smallest dose of MEDI, gave in a phase II trial of human digestive tract tumors (at the dose of 400 mg/m2 per month determined by the phase I trial), 30% objective remissions among which 13% were greater than 50%.

This publication has 0 references indexed in Scilit: